post of the day

featured

Q&A December

This month it is Thailand day so we have the Siamese fighting Fish This is the count down to a new year and change….. Sculptures from the East End of London In the New Year this will appear Weekly such that the threads are manageable Disclaimer: Please note that the opinions expressed here are those of the author and do not reflect the positions of the Barts and The London School...

Latest stories

Q&A December

This month it is Thailand day so we have the Siamese fighting Fish This is the count down to a new year and change….. Sculptures from the East End of London In the New Year this will appear Weekly such that the threads are manageable Disclaimer: Please note that the opinions expressed here are those of the author and do not reflect the positions of the Barts and The London School...

A rare life-threatening adverse event on Copaxone

Odd as it may seem, one of the safest DMTs in the MS world, Glatiramer acetate (Copaxone) can also give some nasty rare side effects. In this unfortunate lady the drug-related side effect involved her breasts (apologies for the pictures if it is distressing to some of our readers). But, in a previous case report a generalized skin vasculitis has also been described (see abstract below). An...

Cladribine and Childhood Immunity

Some Scientists appear to get trained not to speculate but do the experiment and show the data. This makes for nice science where you dot the i’s and cross the t’s. However, it is drain on resource and time, especially if you have to do the work yourself. However, it also makes sure no-one steals you ideas. However ideas are “ten a penny” and if you are having the idea...

How does EBV influence MS

EBV appears to central to MS and other conditions. The big question is how? This is important because it depends on the the effect that you may get if you try and inhibit it. Some people think it is a target and so if you get rid of it, you get rid of MS. Most of the MS science world is not convinced and this is why it is difficult to get support to do trials. As it is sunday and if you are...

Cladribine

No sooner has the Polish bus rolled up, ProfK drives our team Bus and our work has been published relating to the longer term effects of cladribine treatment Allen-Philby et al. Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients Therapeutic advaneces in Neurological disorders. Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak®) in...

BLACK FRIDAY COVID BREAKFAST TO CHRISTMAS CHEER TO REDUCE RISK OF MS?

Today is black friday. Not because of the post thanksgiving sales but because with London Tube strikes is is going to be a bleak friday travelling to work. So work from home, do abit of retail therapy and dont rush out. Sit back and have some brekkie. I havent done one of these for a long time but maybe mice are going to get it (COVID-19) So as you choke on your rice crispies at the thought of...

Long term safety of subcutaneous cladribine

Cladribine as an immune reconstituion therapy that is given over 4 courses over a year and a bit and then that is it for 4 years. But what happens next? If we look at alemtuzumab about 50% fail after their two courses and are given more antibody and about 50% fail who are given three courses, but it is an effective drug. So if you fail cladribine should you get another course of switch treatment...

New treatment arrival in UK

Diroximel fumarate is a new treatment used for the treatment of relapsing forms of multiple sclerosis (MS). Diroximel fumarate was approved for medical use in the United States in October 2019 and has now been approved in the UK and is awaiting final approval by the European Comission in the EU. Dimethyl fumarate works because it is metabolized to monomethyl fumarate. Diroximel...

ProfG past posts are on MS Selfie site

For those of you who are interested and horrified. ProfG has moved all his posts on to his MS selfie web site

Disclaimer: Please note that the opinions expressed there are those of Prof Giovannoni and do not reflect the positions of the Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust or Queen Mary Univeristy of London.

Teriflunomide fails in Paediatric MS for primary outcome

Teriflunomide (Aubagio) holds a license for adult RRMS with an efficacy of roughly 30% relapse rate reduction versus placebo (dummy tablet). The long awaited study in paediatric MS (TERIKIDS study) recently published, however has failed to meet its primary endpoint – time to first confirmed clinical relapse in the teriflunomide group vs. placebo. The probability of first confirmed relapse...

Translate

Categories

Recent Posts

Recent Comments

Archives